Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.24 USD | +29.38% | +22.43% | +24.17% |
Apr. 17 | Deals of the day-Mergers and acquisitions | RE |
Apr. 17 | Sector Update: Health Care Stocks Retreating Late Afternoon | MT |
Financials (USD)
Sales 2022 | 254M | Sales 2023 | 193M | Capitalization | 243M |
---|---|---|---|---|---|
Net income 2022 | 6M | Net income 2023 | 2M | EV / Sales 2022 | -0.15 x |
Net cash position 2022 | 456M | Net cash position 2023 | 379M | EV / Sales 2023 | -0.71 x |
P/E ratio 2022 |
67.2
x | P/E ratio 2023 |
106
x | Employees | 203 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.79% |
Latest transcript on Vanda Pharmaceuticals Inc.
1 day | +1.91% | ||
1 week | +22.43% | ||
Current month | +27.49% | ||
1 month | +39.73% | ||
3 months | +39.36% | ||
6 months | +16.70% | ||
Current year | +24.17% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 02-10-31 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 12-11-30 |
Scott Howell
HRO | Human Resources Officer | - | 19-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard W. Dugan
BRD | Director/Board Member | 82 | 05-11-30 |
Chief Executive Officer | 64 | 02-10-31 | |
Director/Board Member | 72 | 20-02-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.34% | 29 M€ | -6.73% | ||
0.22% | 27 M€ | -6.65% | - | |
0.05% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-17 | 5.24 | +29.38% | 24,015,713 |
24-04-16 | 4.05 | -0.25% | 790,418 |
24-04-15 | 4.06 | -1.46% | 787,157 |
24-04-12 | 4.12 | -3.74% | 762,864 |
24-04-11 | 4.28 | 0.00% | 766,830 |
Delayed Quote Nasdaq, April 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.17% | 233M | |
-3.39% | 102B | |
+2.61% | 96.09B | |
-1.02% | 22.05B | |
-18.14% | 20.81B | |
-6.87% | 19.06B | |
-40.70% | 16.05B | |
-26.89% | 14.01B | |
+1.12% | 13.38B | |
+22.25% | 11.01B |
- Stock Market
- Equities
- VNDA Stock